SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
The UHS Heart & Vascular Institute recently celebrated a significant milestone with the completion of their 1,000th TAVR (Transcatheter Aortic Valve Replacement) procedure. This achievement is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback